Finding new ways to identify and treat the most aggressive type of DLBCL
In this project, Dr Calado will try and understand more about why some types of DLBCL stop responding to treatment.
The challenge
Diffuse large B cell lymphoma (DLBCL) is an aggressive type of lymphoma that can be treated, but some people have lymphoma that doesn’t respond well to therapy which means they see their cancer return. We need to understand how some types of DLBCL resist treatment.
The project
There are certain features of some types of DLBCL that are known to make the disease less likely to respond to treatment, but this is very difficult to study and difficult to test people for. In this project, Dr Calado and his team want to create a new model of the disease so they can understand more about how certain lymphomas resist treatment and how we might predict this. They then want to see if they can find ways to stop this from happening.
The future
The hope is that this work could lead to new treatments being developed for DLBCL to try and reduce the chance of relapse in the most aggressive types of the disease.
What our community think
“There is a real unmet need for research on cancers that are resistant to existing treatments. The type of blood cancer being studied is amongst the most difficult to treat.”
- Patient Voice Grant Advisory Network Member, in remission from non-Hodgkin lymphoma